Business Context and Reporting Period
This Form 8-K is filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) for the reporting period ending January 31, 2019. The registrant is a Delaware corporation headquartered in San Diego, CA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and regulatory compliance events rather than financial performance data.
Material Changes
- Series C Preferred Stock: On January 31, 2019, the Company filed an amendment to the Certificate of Designation for its Series C Convertible Preferred Stock, which limited the voting rights of this stock class.
- Nasdaq Listing Status: The Nasdaq Hearings Panel granted an extension of the deadline to evidence compliance with the minimum bid price requirement ($1.00 per share for 10 consecutive trading days) from January 31, 2019, to March 6, 2019.
Guidance, Outlook, and Risks
Management is taking definitive steps to comply with Nasdaq listing requirements, including seeking shareholder approval for a reverse stock split. However, the Company explicitly states there can be no assurance that it will be able to achieve compliance or successfully implement the reverse stock split. Failure to comply could result in delisting.
Investor Verification Checklist
- Verify the current stock price and whether the $1.00 minimum bid price requirement has been met by the March 6, 2019 deadline.
- Confirm the status of the shareholder vote regarding the proposed reverse stock split.
- Review the specific terms of the amended Series C Convertible Preferred Stock to understand the impact of limited voting rights.
- Check for subsequent filings regarding potential delisting notices from Nasdaq.